HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wei, L. Articles by Lewis, J. S. Search for Related Content PubMed PubMed Citation Articles by Wei, L. Articles by Lewis, J. S.

Synthesis and Biologic Evaluation of ⁶⁴Cu-Labeled Rhenium-Cyclized -MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator

¹ Division of Radiological Sciences, Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; and ² Department of Biochemistry, University of Missouri-Columbia, Columbia, Missouri

Correspondence: For correspondence or reprints contact: Jason S. Lewis, PhD, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd., Campus Box 8225, St. Louis, MO 63110. E-mail: j.s.lewis{at}wustl.edu

Early detection of cutaneous melanoma is essential, as prognosis with metastatic melanoma is poor. Previous studies showed that ⁶⁴Cu-DOTA-ReCCMSH(Arg¹¹) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid), a cyclic analog of -melanocyte-stimulating hormone (-MSH), has the potential for the detection of malignant melanoma using PET. However, ⁶⁴Cu-DOTA-ReCCMSH(Arg¹¹) demonstrated high background in nontarget tissues due to the in vivo instability of the Cu-DOTA moiety. CBTE2A (CBTE2A is 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane) has been shown to be a more stable copper chelate with improved in vivo stability, resulting in an improvement in clearance from nontarget tissues. The goal of this study was to conjugate CBTE2A to the -MSH targeting ReCCMSH(Arg¹¹) peptide for labeling to ⁶⁴Cu and to investigate whether the increased metal-chelate stability with CBTE2A would improve imaging quality. Methods: The recyclized peptide CBTE2A-ReCCMSH(Arg¹¹) was synthesized using a solid-phase peptide synthesizer followed by rhenium cyclization. In vivo characteristics of ⁶⁴Cu-CBTE2A-ReCCMSH(Arg¹¹) were examined with small-animal PET and acute biodistribution studies in B16/F1 tumor-bearing mice. Results: Biodistribution studies showed high and rapid receptor-mediated tumor uptake with values similar to those reported for ⁶⁴Cu- and ⁸⁶Y-labeled DOTA-ReCCMSH(Arg¹¹). Nontarget organ concentration for ⁶⁴Cu-CBTE2A-ReCCMSH(Arg¹¹) was considerably lower than that of the ⁶⁴Cu-DOTA analog, resulting in significantly higher tumor-to-nontarget tissue ratios. Compared with ⁸⁶Y-DOTA-ReCCMSH(Arg¹¹), ⁶⁴Cu-CBTE2A-ReCCMSH(Arg¹¹) demonstrated increased tumor retention and kidney clearance. Small-animal PET images showed that the tumor could be clearly visualized at all time points (0.5–24 h). Conclusion: Our data suggest the superior stability of the ⁶⁴Cu-CBTE2A moiety compared with ⁶⁴Cu-DOTA, making ⁶⁴Cu-CBTE2A-ReCCMSH(Arg¹¹) an ideal candidate for the PET of malignant melanoma.

Key Words: melanoma • -melanocyte-stimulating hormone • small-animal PET • ⁶⁴Cu

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]